View on market: Stay Cautious, be with quality business:

Asian stocks and U.S. equity futures rose early Friday after solid U.S. economic data and President Joe Biden’s federal spending plans spurred a rally on Wall Street in cyclical shares. Japan led gains, jumping more than 1%, with South Korea and Australia also up. S&P 500 and Nasdaq 100 futures advanced. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, rose 0.25% to 15,453 as of 8:02 a.m. The 10-year U.S. Treasury yield advanced past 1.61% amid the growth optimism and focus on debt supply risks to fund spending.

.Key Data/ Action, Result, and Board meeting to watch

Major economic Data:

  • INR: Foreign Exchange Reserves on 28th May, 2021
  • INR: Infrastructure Output on 31st May, 2021
  • INR: GDP Growth Rate YoY Q1on 31st May, 2021

International Markets:

U.S & Europe

Particulars    27th May. Chg Chg(%)
Nasdaq 13,736.28 -1.72 -0.01
Dow 34464.64 141.59 0.41
FTSE 7,019.67 -7.26 -0.1
CAC 6,435.71 44.11 0.69
DAX 15,406.73 -43.99 -0.28
Dow Fut.* 34,593.50 156.5 0.45

Asian markets:

Particulars    28th May. Chg Chg(%)
SGX Nifty 15,482.00 68 0.44
Nikkei 29,125.95 576.94 2.02
Straits Times 3,190.85 26.03 0.82
Hang Seng 29,293.61 180.41 0.62
Shanghai 3,612.50 3.65 0.1

ADR Watch:

Particulars       27th May. Chg Chg(%)
Dr Reddy 72.22 0.25 0.35
HDFC Bank 75.63 1.67 2.26
ICICI Bank 18.17 0.2 1.11
Infosys 19.37 0.11 0.57
Tata Motor 22.18 0.42 1.93
Wipro 7.92 0.09 1.15

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR        72.59 -0.25
Brent 69.38 0.26
Gold 1894.30 -0.07
Silver 27.872 -0.24

FIIs & DII

Particulars        27th May.    26th May.
FIIs  -660.90     241.60
DIIs   112.38  -438.59

Earnings to Watch:

Nifty Earning: Mahindra and Mahindra

Non-Nifty Earnings: Jindal Poly Film,Max Healthcare Institute, NACL Industries, Navkar Corporation, NCC, NESCO, OnMobile Global, Rajapalayam Mills, REC, Reliance Infrastructure, Renaissance Global, 3M INDIA, Aditya Birla Fashion and Retail, Action Construction Equipment, Ador Welding, Associated Alcohols & Breweries, Bengal & Assam Company, Camlin Fine Sciences, Central Bank Of India, Confidence Petroleum India, Dilip Buildcon, Deepak Fertilisers & Petrochemicals Corporation, Prataap Snacks, Excel Industries, Force Motors, Genus Power Infrastructures, Glenmark Pharmaceuticals, GMM Pfaudler, Gulf Oil Lubricants India, Heidelbergcement India, Hinduja Global Solutions, Indian Bank, India Nippon Electricals, Ipca Laboratories, ITD Cementation India, Jagran Prakashan, , Kama Holdings, Kanoria Chemicals & Industries, RSWM, SMS Pharmaceuticals, Sudarshan Chemical Industries, Sumitomo Chemical India, Time Technoplast, TV Today Network, Ujjivan Financial Services, V-Mart Retail, WPIL

Results:

Dixon Technologies Q4FY21 (Consolidated, QoQ) Revenue down 3% at Rs 2,109.71 crore Vs Rs 2,182.78 crore (Bloomberg estimate: Rs 2,015.3) Net profit down 28% at Rs 44.26 crore Vs Rs 61.59 crore (estimate: Rs 54.5 crore) Ebitda down 21% at Rs 79.81 crore Vs Rs 100.5 crore (estimate: Rs 98.1 crore) Ebitda margin at 3.8% Vs 4.6% (estimate: 4.86%) Recommended final dividend of Re 1 per share Approved upto Rs.500 crore Fund Raising Plan.

Eicher Motors Q4FY21 (Consolidated, QoQ) Revenue up 4% at Rs 2,940 crore Vs Rs 2,828 crore (Bloomberg estimate: Rs 2,903 crore) Profit down 1% at Rs 526 crore Vs Rs 533 crore (estimate: Rs 566 crore).

Sun Pharmaceutical Industries Q4FY21 (Consolidated, QoQ) Revenue down 4% at Rs 8,522.90 crore Vs Rs 8,836.70 crore (Bloomberg estimate: Rs 8,716 crore) Net profit down 52% at Rs 894.10 crore Vs Rs 1,852.40 crore (estimate: Rs 1,375 crore). India sales up 12.9% at Rs 2,670.9 crore (YoY) U.S. finished dosage sales down 1.3% at $370 million (YoY) Rest of World sales up 5.5%.

India Grid Trust: Net profit down 28% quarter-on-quarter at Rs 67.90 crore Vs Rs 94.50 crore. Q4FY21 distribution up 3.3% at Rs 3.10 per unit. FY22 distribution guidance raised to Rs 12.75 per unit.

News Update:

Hester Biosciences | The company will provide infrastructure for manufacturing COVAXIN drug substance and has estimated an outlay of Rs 40 crore for this project.

UCO Bank | The bank’s board has approved raising Rs 3,000 crore equity capital for the financial year 2021-22.

Navneet Education | The company’s board has approved Rs 50 crore worth share buyback at Rs 100 per share.

NLC India | The company has issued and allotted commercial papers worth Rs 300 crore.

TCS: Completed the acquisition of GE’s stake in Tata Consultancy Services Saudi Arabia on May 26.

Authum Investment & Infrastructure: Approved raising of funds up to Rs 500 crore by way of QIP, preferential allotment. The company has also approved a sub-division of one share of the face value of Rs 10 each fully paid up into 10 shares of Re 1 each fully paid up.
Panacea Biotech: To consider raising funds in June 2 meeting.

Source: Moneycontrol, Livemint,, Bloomberg, Investing, Business Standard

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.Company-Specific Disclosures Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in , or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person. Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company in the analyst’s area of coverage. Country Specific Disclosures India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking
or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.